FacebookTwitterInstagramPinterest
Monday - Friday, 9 a.m. - 5 p.m.|(877) 240-1660

Investment Opportunities

Investment Opportunities2020-10-21T05:51:25+00:00

The global center nervous system therapeutic market was worth USD 77.2 billion in 2016 and is anticipated to grow at a CAGR of 5.9%

Venture into the biomedical research market or extend your reach into it by investing in RBI, Inc. Your funding will help us continue making inroads into the field of stem cell research and treatments. Contact us for additional details about investing.

Our proprietary delivery method solves the problems of:

  • Accessing the center of the brain, and the brain’s lymphatic system.
  • Getting IV or oral medications to cross the blood brain barrier.
  • Lumbar puncture administration where cells merely settle to the bottom of the spinal canal.
  • Multiple painful spinal taps to administer the cells into the cerebrospinal fluid. It allows unlimited, painless, dosing for years and years.
  • Cells causing CSF outflow problems. Delivery port acts as a safety valve in case of any problems of elevated intracranial pressure.
  • Multiple Painful spinal taps to draw off cerebrospinal fluid for testing and other treatments in the future.

Provisional Patent Applications

  • WNT-activated adipose-derived stem cell apparatuses, methods and systems.
  • Methods and apparatuses for instilling stem cells and pharmaceuticals into the human ventricular system.

RBI, Inc. is set to make a mark in the treatment of neurodegenerative diseases. By making a biomedical investment with our company, you help us continue our work on effective treatments for Alzheimer’s, ALS, and Parkinson’s disease. The following is a timeline of where this area of medical research stands, including successes and failures.

Strategy

Probable Multifactorial Etiologies for Neurodegenerative Diseases – A stem cell can address many targets at once. We feel it is naive to believe that a single gene alteration, or genetic change can effect a clinical change, in diseases that are most certainly multifactorial. Finally, we begged the question: if a stem cell is genetically altered, does it still act as a pluripotential stem cell?

The Numerous Classes of Neurodegenerative Drugs That Have Failed to Date – This includes the monoclonal antibodies, the gamma-secretase inhibitors, neurochemical enhancers, and targeting drugs.

Failure to Produce Desired Effects – The inefficacy of current FDA approved drugs to alter the course of neurodegenerative diseases.

Relying on a Single Dose – We offer the ability to bank and multiply cells by factors of 10 or 100s at our discretion and deliver dosing over years and years.

Rejection and Potential Immune Responses against Allogeneic Cell Alternatives – This involves the safer use of autologous cells versus allogeneic.

Medical Tourism – Patients will sometimes travel to receive a single stem cell injection, usually IV; and cells are stopped by the lung.

Genetically Modified Cells – Does a genetically modified stem cell still act like a stem cell?

Lack of Pharmaceutical Alternatives – There are no FDA-approved drugs for progressive multiple sclerosis, traumatic brain injury, and Parkinson’s “plus” syndromes. And only a single ineffective drug approved for ALS.

Discover The Future

Our company is at the forefront of the biomedical research industry thanks to professionals who have had more than 30 years of medical and research experience.

Contact Us
3900 West Coast Hwy Suite 300 Newport Beach California 92663 | Phone: 1-877-240-1660 Fax: 1-949-480-0657
© Copyright  Regeneration Biomedical, Inc. All Rights Reserved.
Skip to content

  • CEREWiNT® Phase 1 Clinical Safety Trial

    Hoag Hospital – Newport Beach

    The basic outline of our protocol is simple. Here are the steps a Participant will go through:

    1. To be enrolled in Regeneration Biomedical’s Phase 1 Safety Trial for CEREWiNT®, a Participant must first be diagnosed by a physician to have Alzheimer’s disease and confirmed to meet all the Inclusion/Exclusion Criteria found on the Inclusion/Exclusion Criteria Page.
    2. A Participant must have a designated caregiver that will help them get to and from their appointments and procedures. The Caregiver Inclusion/Exclusion Criteria can also be found on the Inclusion/Exclusion Criteria Page. All participants will meet with a physician or study coordinator and be given information regarding any risks, as well as a detailed explanation of all tests and procedures involved in the study and be required to give their own Informed Consent.
    3. Once a Participant has been qualified as eligible, the participants will have their own personal fat cells collected via a lipoaspirate procedure (also known as liposuction – removing fat from the abdominal area) for processing. This will be done as an outpatient procedure at the Hoag Pavilion and will take about 1 hour. During processing, specific stem cells will be selected in a special (proprietary) way and prepared for the next steps. The cell processing takes about 4-6 weeks and at that point the finished product is called “CEREWiNT®”.
    4. An Ommaya Reservoir will need to be implanted (if the Participant doesn’t already have one). An Ommaya reservoir is a flat-bottomed domed bubble which is implanted below the scalp. The reservoir is connected to a catheter which is placed into the hollow cavities of the brain through a hole made in the skull. Implantation of the Ommaya Reservoir and catheter is done via a brief outpatient surgical procedure which takes about 30 minutes.
    5. About 8 weeks after collection, the cells will have been completely processed and will be ready for implantation. The Participant will come into the hospital or infusion center and have the reservoir area of their scalp prepped/sterilized for the procedure. After the Participant’s scalp is prepped, a surgeon will insert a small needle into the Ommaya Reservoir and draw out a small amount of cerebrospinal fluid. The surgeon will then inject the CEREWiNT® into the Ommaya Reservoir after which small amount of the cerebrospinal fluid that was drawn out will be used to flush the Ommaya Reservoir and get as much of the CEREWiNT® into the ventricles of the brain as possible. This entire procedure takes less than 30 minutes.***
    6. The Participant will remain in the hospital over-night, be monitored for 24 hours, and have a next day visit with their surgeon.
    7. The Participant will be monitored and tested for the next 52 weeks. This is a Phase 1 safety only trial. Each Participant will receive only one injection and safety will be assessed.
    8. This Phase 1 Safety Trial lays the groundwork for Phase 2 efficacy trial. Participants in Phase 1 may have the option of rolling over into a parallel treatment group to the Phase 2 trial.
    9. This document is for information purposes only; a more thorough informed consent will be given to the Participant prior to the start of the trial, for signature.

    *** It is important to understand that there are risks involved in any safety trial. Some of the risks include bleeding, swelling, infection, discomfort, headache, and the possibility of additional surgery to name a few. A complete list of potential risks will be provided and completely explained to potential participants.

    Inclusion Criteria

    • Go to Top